共查询到20条相似文献，搜索用时 0 毫秒
1.
Shu Huaqing Wang Shuzhen Ruan Shunan Wang Yaxin Zhang Jiancheng Yuan Yin Liu Hong Wu Yongran Li Ruiting Pan Shangwen Ouyang Yaqi Yuan Shiying Zhou Peng Shang You 《中国病毒学》2020,35(6):744-751
Virologica Sinica - The coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has spread around the world with high mortality. To diagnose promptly and accurately is the vital step to... 相似文献
2.
Wang Shichuan Trilling Mirko Sutter Kathrin Dittmer Ulf Lu Mengji Zheng Xin Yang Dongliang Liu Jia 《中国病毒学》2020,35(6):673-684
Virologica Sinica - The recent emergence and rapid global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pose an unprecedented medical and socioeconomic crisis, and the... 相似文献
3.
Tian Suyan Zhu Xuetong Sun Xuejuan Wang Jinmei Zhou Qi Wang Chi Chen Li Li Shanji Xu Jiancheng 《中国病毒学》2020,35(6):811-819
Virologica Sinica - The temporal change patterns of laboratory data may provide insightful clues into the whole course of COVID-19. This study aimed to evaluate longitudinal change patterns of key... 相似文献
4.
Jia Lu Qiangling Yin Rongjuan Pei Qiu Zhang Yuanyuan Qu Yongbing Pan Lina Sun Ding Gao Cuiqin Liang Jingwen Yang Wei Wu Jiandong Li Zongqiang Cui Zejun Wang Xinguo Li Dexin Li Shiwen Wang Kai Duan Wuxiang Guan Mifang Liang Xiaoming Yang 《中国病毒学》2022,37(2):238-247
Multiple new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have constantly emerged, as the delta and omicron variants, which have developed resistance to currently gained neutralizing antibodies. This highlights a critical need to discover new therapeutic agents to overcome the variants mutations. Despite the availability of vaccines against coronavirus disease 2019 (COVID-19), the use of broadly neutralizing antibodies has been considered as an alternative way for the prevention or treatment of SARS-CoV-2 variants infection. Here, we show that the nasal delivery of two previously characterized broadly neutralizing antibodies (F61 and H121) protected K18-hACE2 mice against lethal challenge with SARS-CoV-2 variants. The broadly protective efficacy of the F61 or F61/F121 cocktail antibodies was evaluated by lethal challenge with the wild strain (WIV04) and multiple variants, including beta (B.1.351), delta (B.1.617.2), and omicron (B.1.1.529) at 200 or 1000 TCID50, and the minimum antibody administration doses (5-1.25 mg/kg body weight) were also evaluated with delta and omicron challenge. Fully prophylactic protections were found in all challenged groups with both F61 and F61/H121 combination at the administration dose of 20 mg/kg body weight, and corresponding mice lung viral RNA showed negative, with almost all alveolar septa and cavities remaining normal. Furthermore, low-dose antibody treatment induced significant prophylactic protection against lethal challenge with delta and omicron variants, whereas the F61/H121 combination showed excellent results against omicron infection. Our findings indicated the potential use of broadly neutralizing monoclonal antibodies as prophylactic and therapeutic agent for protection of current emerged SARS-CoV-2 variants infection. 相似文献
5.
Zhang Xiaoyong Lu Suwen Li Hui Wang Yi Lu Zhen Liu Zhihong Lai Qingtao Ji Yali Huang Xuan Li Yongyin Sun Jian Wu Yingsong Xu Xiaoning Hou Jinlin 《中国病毒学》2020,35(6):820-829
Virologica Sinica - Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly around the world, posing a major threat to human... 相似文献
6.
Aline
H. de Nooijer Inge Grondman Simon Lambden Emma
J. Kooistra Nico
A.F. Janssen Matthijs Kox Peter Pickkers Leo
A.B. Joosten Frank
L. van de Veerdonk Marc Derive Sebastien Gibot Mihai
G. Netea 《Bioscience reports》2021,41(7)
Patients with sepsis display increased concentrations of sTREM-1 (soluble Triggering Receptor Expressed on Myeloid cells 1), and a phase II clinical trial focusing on TREM-1 modulation is ongoing. We investigated whether sTREM-1 circulating concentrations are associated with the outcome of patients with coronavirus disease 2019 (COVID-19) to assess the role of this pathway in COVID-19. This observational study was performed in two independent cohorts of patients with COVID-19. Plasma concentrations of sTREM-1 were assessed after ICU admission (pilot cohort) or after COVID-19 diagnosis (validation cohort). Routine laboratory and clinical parameters were collected from electronic patient files. Results showed sTREM-1 plasma concentrations were significantly elevated in patients with COVID-19 (161 [129–196] pg/ml) compared to healthy controls (104 [75–124] pg/ml; P<0.001). Patients with severe COVID-19 needing ICU admission displayed even higher sTREM-1 concentrations compared to less severely ill COVID-19 patients receiving clinical ward-based care (235 [176–319] pg/ml and 195 [139–283] pg/ml, respectively, P = 0.017). In addition, higher sTREM-1 plasma concentrations were observed in patients who did not survive the infection (326 [207–445] pg/ml) compared to survivors (199 [142–278] pg/ml, P<0.001). Survival analyses indicated that patients with higher sTREM-1 concentrations are at higher risk for death (hazard ratio = 3.3, 95%CI: 1.4–7.8). In conclusion, plasma sTREM-1 concentrations are elevated in patients with COVID-19, relate to disease severity, and discriminate between survivors and non-survivors. This suggests that the TREM-1 pathway is involved in the inflammatory reaction and the disease course of COVID-19, and therefore may be considered as a therapeutic target in severely ill patients with COVID-19. 相似文献
7.
Guan Wenyi Lan Wendong Zhang Jing Zhao Shan Ou Junxian Wu Xiaowei Yan Yuqian Wu Jianguo Zhang Qiwei 《中国病毒学》2020,35(6):685-698
Virologica Sinica - The World Health Organization (WHO) has declared coronavirus disease 2019 (COVID-19) is the first pandemic caused by coronavirus named severe acute respiratory syndrome... 相似文献
8.
Recent studies have identified an association between perturbed type I interferon (IFN) responses and the severity of coronavirus disease 2019 (COVID-19). IFNα intervention may normalize the dysregulated innate immunity of COVID-19. However, details regarding its utilization and therapeutic evidence have yet to be systematically evaluated. The aim of this comprehensive review was to summarize the current utilization of IFNα for COVID-19 treatment and to explore the evidence on safety and efficacy. A comprehensive review of clinical studies in the literature prior to December 1st, 2021, was performed to identify the current utilization of IFNα, which included details on the route of administration, the number of patients who received the treatment, the severity at the initiation of treatment, age range, the time from the onset of symptoms to treatment, dose, frequency, and duration as well as safety and efficacy. Encouragingly, no evidence was found against the safety of IFNα treatment for COVID-19. Early intervention, either within five days from the onset of symptoms or at hospital admission, confers better clinical outcomes, whereas late intervention may result in prolonged hospitalization. 相似文献
9.
10.
由严重急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)引起的病毒性肺炎已经扩散到全球200多个国家和地区,导致了数十万人死亡.2019冠状病毒病(coronavirus disease 19,COVID-19)的流行病学、致... 相似文献
11.
12.
2019冠状病毒病(coronavirus disease 2019,COVID-19)是由严重急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)导致的感染性疾病.SARS-CoV-2感染人体后除作用于肺部的SARS-CoV-... 相似文献
13.
Changfu Yao Stephanie A. Bora Tanyalak Parimon Tanzira Zaman Oren A. Friedman Joseph A. Palatinus Nirmala S. Surapaneni Yuri P. Matusov Giuliana Cerro Chiang Alexander G. Kassar Nayan Patel Chelsi E.R. Green Adam W. Aziz Harshpreet Suri Jo Suda Andres A. Lopez Gislâine A. Martins Barry R. Stripp Peter Chen 《Cell reports》2021,34(1):108590
- Download : Download high-res image (182KB)
- Download : Download full-size image
14.
新型冠状病毒肺炎(2019 novel coronavirus disease,COVID-19),一种由动物来源的新型冠状病毒(severe acute respiratory syndrome coronavirus 2,SRAS-CoV-2)感染所致的疾病在全球范围内急速传播,严重的危害人类的健康.快速、准确的诊... 相似文献
15.
《Cell host & microbe》2020,27(5):704-709.e2
- Download : Download high-res image (103KB)
- Download : Download full-size image
16.
严重急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)自被发现以来就引起了人们的广泛关注,开发针对该病毒的安全、有效疫苗成为近期的研究热点。本文以高致病性冠状病毒疫苗(包括灭活疫苗、重组亚单位疫苗、重组病毒载体疫苗和核酸疫苗)的研究展开综述,为研制SARS-CoV-2疫苗提供参考。 相似文献
17.
Wu Yongran Hong Ke Ruan Lianguo Yang Xiaobo Zhang Jiancheng Xu Jiqian Pan Shangwen Ren Lehao Chen Lu Huang Chaolin Shang You 《中国病毒学》2020,35(6):768-775
Virologica Sinica - Convalescent plasma therapy has been implemented in a few cases of severe coronavirus disease 2019. No report about convalescent plasma therapy in treating patients with... 相似文献
18.
抗体药物以其独特的作用机制和靶向性强、特异性好等优点,在恶性肿瘤、自身免疫性疾病、感染类疾病的诊断和治疗中发挥着越来越重要的作用,成为国际创新药物研发的热点。新冠肺炎(COVID-19)疫情发生以来,国内外多家研究机构和企业正在加快推进新冠病毒(SARS-CoV-2)抗体药物的开发。在此情势下,认真分析抗体药物现状和趋势,梳理国内外新冠病毒抗体药物研究进展,明确我国当前抗体药物创新的机遇、挑战和建议,对加快我国药物自主创新研发具有重要意义。 相似文献
19.
20.
2020年新型冠状病毒肺炎(COVID-19)在全球200多个国家蔓延,对世界公共卫生环境、民众生命健康安全与社会经济带来了巨大影响。为了解病毒传播的时空特征及驱动因子对新型冠状病毒(SARS-CoV-2)防控的重要意义,本研究基于2020年1月21日~2020年3月10日浙江省各县、市(区)的COVID-19疫情数据,按照病例数的变化情况将疫情时期分为迅速增长期、高位回落期、控制减少期和稳定期,发现省外输入病例主要确诊于迅速增长期和高位回落期,省内扩散病例主要确诊于控制减少期和稳定期。利用ArcGIS软件进行数据可视化,总结了两种病例类型在浙江省各县、市(区)分布的时空变化特征,发现浙江省新冠肺炎疫情在温州最为严重,其次是杭州、宁波和台州;并利用地理探测器方法探究了各因子的作用,发现社会经济因子和城市建设因子影响较大,自然环境因子影响较小。 相似文献